Monthly Archives: September 2015
Testing and Toxicology of Designer Drugs
This article explains Testing and Toxicology of Designer Drugs and the scientific, legal or practical evidence readers should understand.
This article explains Testing and Toxicology of Designer Drugs and the scientific, legal or practical evidence readers should understand.
Naloxone appeared in 156 of 413 xylazine-positive urine samples in Holt and colleagues’ outpatient testing cohort. That finding alone does not prove a recent overdose or emergency reversal. What the paper counted The researchers reviewed provider-ordered urine toxicology tests from April 2021 through March 2022. In their xylazine-positive group, 156…
Read Article: Does Naloxone in a Xylazine-Positive Urine Sample Prove an Overdose Rescue?
Three of 46 xylazine-positive submissions to Toronto’s Drug Checking Service were associated with a reported overdose. The paper does not establish that xylazine caused any of those three events. What the report actually counted Bowles and colleagues studied drug-checking submissions, not a controlled comparison of overdose outcomes. Within a September…
Read Article: Did Three Overdose-Associated Toronto Samples Prove Xylazine Caused Those Events?
Short answer: If a checked sample does not contain the drug the submitter expected, an unexpected opioid finding may reflect a mistaken or misrepresented sample rather than an opioid added to a confirmed expected drug. Wallace and colleagues treated these as different scenarios in their British Columbia analysis. What was…
Read Article: What If a Drug-Checking Sample Lacks the Drug the Submitter Expected?